Kamis, 31 Desember 2020

Rabu, 30 Desember 2020

China gives its first COVID-19 vaccine approval to Sinopharm - CNA

BEIJING: China approved on Thursday (Dec 31) its first COVID-19 vaccine for general public use, a shot developed by an affiliate of state-backed pharmaceutical giant Sinopharm, as it braces for greater transmission risks over the winter.

No detailed efficacy data of the vaccine has been publicly released but its developer, Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group (CNBG), said on Wednesday its vaccine was 79.34 per cent effective in preventing people from developing the disease based on interim data.

The approval, announced by the National Medical Products Administration, comes after the United Arab Emirates this month became the first country to roll out the vaccine to the public, and as Pakistan announced a 1.2 million dose purchase deal with Sinopharm.

READ: China Sinopharm’s vaccine has 79% protection rate against COVID-19

While China has been slower than several other countries in approving COVID-19 vaccines, it has been inoculating some citizens for months with three different shots still undergoing late-stage trials.

China launched an emergency use programme in July aimed at essential workers and others at high risk of infection, and has administered more than 4.5 million doses as of Dec 15 using at least three different products - two developed by CNBG and one by Sinovac Biotech.

While the efficacy of the Sinopharm shot trails the more than 90 per cent success rate of rival vaccines from Pfizer and its partner BioNTech and Moderna, it points to progress China has made in the global race to develop successful COVID-19 vaccines.

China has at least five vaccines, developed by Sinovac, CNBG units, CanSino Biologics and the Chinese Academy of Sciences, in late-stage trials, underscoring its efforts to develop a homegrown vaccine to challenge Western rivals.

President Xi Jinping has pledged to make China's vaccines a global public good and it has won several large supply deals with countries including Indonesia and Brazil - the most populous countries in Southeast Asia and Latin America respectively.

READ: Chinese COVID-19 vaccines are poised to fill gap, but will they work?

WATCHING THE DATA

The efficacy and safety data of China-made vaccines is being closely watched by many developing countries as they have limited early access to shots developed by Western drugmakers and are looking for alternatives from China and Russia.

"China's approval could boost the credibility of the vaccine," said Dong-yan Jin, a professor at the University of Hong Kong.

"But if the vaccine wants to take a share in the global market, especially in developed countries, more data is necessary."

A Sinopharm executive told a briefing detailed data would be released later and published in scientific journals at home and abroad.

While China has kept new outbreaks of the coronavirus under control, it is ramping up the emergency programme to contain the risks over the winter. The virus emerged a year ago in a market in the central city of Wuhan.

The South China Morning Post newspaper reported that China would vaccinate as many as 50 million people from high-priority groups before the Lunar New Year holiday in February.

"We call on people ... to take an active part in vaccination to protect themselves, family members and others, which is also contributing to global epidemic control," Zeng Yixin, an official with National Health Commission, told a briefing on Thursday.

The price of the vaccine would depend on the scale of use, but the "premise" was that it would be free for the public in China, he said.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMibmh0dHBzOi8vd3d3LmNoYW5uZWxuZXdzYXNpYS5jb20vbmV3cy9hc2lhL2NoaW5hLWdpdmVzLWNvbmRpdGlvbmFsLWFwcHJvdmFsLXNpbm9waGFybS1jb3ZpZC0xOS12YWNjaW5lLTEzODcwNTEw0gEA?oc=5

2020-12-31 05:26:15Z
52781273428748

2 more COVID-19 cases 'preliminarily positive' for new UK strain, including SIA pilot - CNA

SINGAPORE: Two more COVID-19 cases have tested "preliminarily positive" for the new coronavirus strain circulating in the UK, said the Ministry of Health (MOH) on Wednesday (Dec 30).

"Further tests will be conducted to confirm the strain," added MOH.

The two cases, reported by the ministry on Wednesday, are both imported. They are a Singapore Airlines pilot who recently travelled to the UK for work and a work pass holder who arrived from the UK.

The pilot travelled to the UK from Dec 19 to Dec 22.

He was tested on Dec 23 as part of rostered regular testing for air crew members who travel frequently. The test came back negative.

After developing a fever on Dec 26, he sought medical treatment the following day at a general practitioner clinic, where he was swabbed for COVID-19.

His test came back positive for COVID-19 on Dec 29 and he was taken by ambulance to the National Centre for Infectious Diseases (NCID).

The 40-year-old man's serological test came back negative, indicating a likely current infection, said MOH.

READ: Singapore tightens COVID-19 measures for air crew, including more frequent PCR tests

SYMPTOMS DEVELOPED AFTER STAY-HOME NOTICE ENDED

The work pass holder arrived from the UK on Dec 7 and was placed on stay-home notice at a dedicated facility upon arrival.

He was tested on Dec 17 and the result came back negative.

After his stay-home notice ended on Dec 21, he started to develop body ache on Dec 22 and symptoms of acute respiratory infection on Dec 25.

He sought medical treatment on Dec 28 and was swabbed for COVID-19.

His test result came back positive on Dec 29 and he was brought to NCID in an ambulance.

The 53-year-old British man's serological test result has come back positive.

READ: Singapore reports 27 new COVID-19 cases, including SIA pilot who initially tested negative

A total of 26 imported cases were reported by MOH on Wednesday.

There was also a community case, a marine surveyor at Lloyd’s Register Singapore who works on board vessels docked at Sembcorp Marine Admiralty Yard.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMiaGh0dHBzOi8vd3d3LmNoYW5uZWxuZXdzYXNpYS5jb20vbmV3cy9zaW5nYXBvcmUvY292aWQtMTktY2FzZXMtbmV3LXVrLWNvcm9uYXZpcnVzLXN0cmFpbi12YXJpYW50LTEzODY3NDcy0gEA?oc=5

2020-12-30 14:58:43Z
52781276231824

Link between COVID-19 shot, Swiss death 'highly unlikely', says drugs regulator - CNA

ZURICH: Swiss drugs regulator Swissmedic on Wednesday (Dec 30) said it saw no link between the death of a 91-year old person in the canton of Lucerne and the COVID-19 vaccine, adding the deceased suffered from multiple illnesses before getting the shot.

"Clarifications by cantonal health authorities and Swissmedic determined that, as a result of the illness history and disease course, a link between the death and the COVID-19 vaccine was highly unlikely," the regulator said in a statement.

Swissmedic said previous illnesses would be listed on the death certificate as the person's "natural cause of death".

READ: Vaccinated US nurse contracts COVID-19, expert says Pfizer shot needed more time to work - report

Lucerne was the site of the first vaccinations in Switzerland last week, with a shot from Pfizer and its German partner BioNTech given primarily to elderly people.

Switzerland has received 107,000 Pfizer/BioNTech doses so far, and expects to get 250,000 per month starting next year.

Neither Lucerne nor Swissmedic released the time that elapsed between the person receiving the shot and when the death occurred. The person's gender was not given.

Pfizer and BioNTech's vaccine is the only inoculation approved so far in Switzerland. It was approved on an emergency basis in the United States and Britain, and has conditional marketing approval in the European Union after trials in tens of thousands of people.

Pfizer said its thoughts were with the deceased's family.

"It is important to note that serious adverse events, including deaths that are unrelated to the vaccine, are unfortunately likely to occur at a similar rate as they would in the general population of elderly and at-risk individuals who are currently being prioritized for vaccination," the US-based company said.

Millions of doses of the vaccine have been administered. Several people have suffered allergic reactions following shots, though those incidents were resolved quickly.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMiZGh0dHBzOi8vd3d3LmNoYW5uZWxuZXdzYXNpYS5jb20vbmV3cy93b3JsZC9jb3ZpZC0xOS12YWNjaW5lLXBmaXplci1zd2lzcy1kaWVzLWxpbmstdW5saWtlbHktMTM4NjY4MTjSAQA?oc=5

2020-12-30 16:18:45Z
CBMiZGh0dHBzOi8vd3d3LmNoYW5uZWxuZXdzYXNpYS5jb20vbmV3cy93b3JsZC9jb3ZpZC0xOS12YWNjaW5lLXBmaXplci1zd2lzcy1kaWVzLWxpbmstdW5saWtlbHktMTM4NjY4MTjSAQA

Preliminary tests show two more in Singapore have UK Covid-19 strain - The Straits Times

SINGAPORE - A Singapore Airlines pilot and a work pass holder have tested preliminarily positive for the new B117 strain of the coronavirus that is circulating in the United Kingdom.

They were among 27 new coronavirus cases confirmed on Wednesday (Dec 30), taking Singapore's total to 58,569.

The pilot, a 40-year-old Singaporean man, had travelled to the United Kingdom for work between Dec 19 and 22, said the Ministry of Health (MOH) on Wednesday (Dec 30).

He was tested on Dec 23 as part of rostered routine testing conducted for air crew who travel frequently.

Although he tested negative for Covid-19 upon returning to Singapore, he developed a fever on Dec 26 and sought medical treatment at a general practitioner clinic the next day, where he was swabbed and confirmed positive on Dec 29.

He was then taken to the National Centre for Infectious Diseases by ambulance.

Serological tests indicate that he is likely to have a current infection, said the Health Ministry.

Further tests will be conducted to confirm the Covid-19 strain the man has.

The work pass holder who also tested preliminarily positive for the B117 strain is a 53-year-old man who returned from the United Kingdom.

Although he ended his stay-home notice on Dec 21, he developed body aches the next day and acute respiratory symptoms on Dec 25.

He was then confirmed positive for Covid-19 on Dec 29.

Meanwhile, there were 24 other imported cases, all of whom had been placed on stay-home notice or isolated on arrival in Singapore, said MOH.

Among the imported cases, three are Singaporean, four are permanent residents, five are work pass holders and seven are work permit holders.

Of the seven work permit holders, six are foreign domestic workers.

The imported cases also include three dependant's pass holders, one long-term visit pass holder, one short-term visit pass holder and one special pass holder.

The sole community case announced on Wednesday (Dec 30) is a permanent resident who works as a marine surveyor at Lloyd's Register Singapore.

As part of his job, the 46-year-old man works on board vessels docked at Sembcorp Marine Admiralty Yard.

He had not gone to work since the onset of symptoms on Dec 27.

His case is currently unlinked and epidemiological investigations are ongoing, said MOH.

MOH added that all the identified close contacts of the cases have been isolated and placed on quarantine.

They will be tested at the start and end of their quarantine period so the ministry can detect asymptomatic cases.

Marina Bay Sands, IMM, Takashimaya and Orchard Gateway were among places visited by Covid-19 patients while they were still infectious, said MOH.

MOH provides the list of locations that infectious Covid-19 patients visited for at least 30 minutes and the times they visited them to get people who were at those places at the same time to monitor their health closely for two weeks from the date of their visit.

The full list of locations and times can be found on the gov.sg website.

MOH has said close contacts would already have been notified and that there is no need to avoid those places as they would have been cleaned if necessary.

Overall, the number of new cases in the community has remained low,with a total of two cases in the past week who are currently unlinked.

With 11 cases discharged on Wednesday, 58,396 patients have fully recovered from the disease.

A total of 52 patients remain in hospital, while 77 are recuperating in community facilities. None is in intensive care.

Singapore has had 29 deaths from Covid-19 complications, while 15 who tested positive have died of other causes.

Related Stories: 

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMiamh0dHBzOi8vd3d3LnN0cmFpdHN0aW1lcy5jb20vc2luZ2Fwb3JlL2hlYWx0aC9wcmVsaW1pbmFyeS10ZXN0cy1zaG93LXR3by1tb3JlLWhlcmUtaGF2ZS11ay1jb3ZpZC0xOS1zdHJhaW7SAQA?oc=5

2020-12-30 14:49:51Z
52781276439340

China, EU leaders conclude investment deal talks via video link - South China Morning Post

[unable to retrieve full-text content]

  1. China, EU leaders conclude investment deal talks via video link  South China Morning Post
  2. Are the EU and China on brink of investment deal?  The Straits Times
  3. EU seeks to rebalance China ties with investment agreement  CNA
  4. Rapid recovery leaves China better placed for 2021 than US or Europe  South China Morning Post
  5. EU, China seal long-awaited investment deal to open Chinese market  The Straits Times
  6. View Full coverage on Google News

https://news.google.com/__i/rss/rd/articles/CBMibGh0dHBzOi8vd3d3LnNjbXAuY29tL25ld3MvY2hpbmEvZGlwbG9tYWN5L2FydGljbGUvMzExNTg5Mi9jaGluYS1ldS1pbnZlc3RtZW50LWRlYWwtbGVhZGVycy1jb25jbHVkZS1tYXJhdGhvbtIBbGh0dHBzOi8vYW1wLnNjbXAuY29tL25ld3MvY2hpbmEvZGlwbG9tYWN5L2FydGljbGUvMzExNTg5Mi9jaGluYS1ldS1pbnZlc3RtZW50LWRlYWwtbGVhZGVycy1jb25jbHVkZS1tYXJhdGhvbg?oc=5

2020-12-30 14:39:01Z
52781272407151

US nurse tests positive over a week after receiving first dose of Pfizer Covid-19 vaccine - AsiaOne

WASHINGTON - A 45-year-old nurse in California tested positive for Covid-19 more than a week after receiving Pfizer's coronavirus vaccine, an ABC News affiliate reported on Tuesday (Dec 29).

Mr Matthew W., a nurse at two different local hospitals, said in a Facebook post on Dec 18 that he had received the Pfizer vaccine, telling the ABC News affiliate that his arm was sore for a day but that he had suffered no other side effects.

Six days later, on Christmas Eve, he became sick after working a shift in the Covid-19 unit, the report added. He got the chills and later came down with muscle aches and fatigue.

He went to a drive-up hospital testing site and tested positive for Covid-19 the day after Christmas, the report said.

[[nid:513408]]

Dr Christian Ramers, an infectious disease specialist with Family Health Centres of San Diego, told the ABC News affiliate that this scenario was not unexpected.

"We know from the vaccine clinical trials that it's going to take about 10 to 14 days for you to start to develop protection from the vaccine," Dr Ramers said.

"That first dose we think gives you somewhere around 50 per cent, and you need that second dose to get up to 95 per cent," Dr Ramers added.

For the latest updates on the coronavirus, visit here.

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMicmh0dHBzOi8vd3d3LmFzaWFvbmUuY29tL3dvcmxkL3VzLW51cnNlLXRlc3RzLXBvc2l0aXZlLW92ZXItd2Vlay1hZnRlci1yZWNlaXZpbmctZmlyc3QtZG9zZS1wZml6ZXItY292aWQtMTktdmFjY2luZdIBdmh0dHBzOi8vd3d3LmFzaWFvbmUuY29tL3dvcmxkL3VzLW51cnNlLXRlc3RzLXBvc2l0aXZlLW92ZXItd2Vlay1hZnRlci1yZWNlaXZpbmctZmlyc3QtZG9zZS1wZml6ZXItY292aWQtMTktdmFjY2luZT9hbXA?oc=5

2020-12-30 09:26:50Z
52781275421818